The use of Benincasa hispida for the treatment of uninvestigated dyspepsia: Preliminary results of a non-randomised open label pilot clinical trial

被引:2
|
作者
Vinaya, T. M. [1 ]
Aravind, B. S. [2 ]
Sibbritt, David [3 ]
Tapasbrata, Tripathy [4 ]
Shivakumar, S. [4 ]
机构
[1] JSS Ayurveda Med Coll, Dept Community Hlth & Prevent Med, Mysore 570028, Karnataka, India
[2] JSS Ayurveda Med Coll, Dept Physiol, Mysore, Karnataka, India
[3] Univ Technol Sydney, Fac Hlth, Ultimo, NSW 2007, Australia
[4] SDM Coll Ayurveda, Dept Community Hlth & Prevent Med, Hassan, Karnataka, India
关键词
Dyspepsia; Benincasa hispida; Ayurveda;
D O I
10.1016/j.aimed.2015.09.003
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Dyspepsia is becoming a common health problem for which an individual seeks medical help. The approach to the management of dyspepsia is complex with high treatment costs and possible adverse effects. Methods: A prospective pilot study was designed to assess the effectiveness of the fruit juice of Ash Gourd (Benincasa hispida) on twenty dyspeptic subjects, who were followed up for 45 days. Measures of retrosternal pain, post-prandial fullness, bloating, sour belching, nausea, vomiting and changes in bowel habits were taken at three times periods (baseline, 30 days and 45 days). Results: Statistically significant improvements were seen in several parameters, including pain (p<0.001), retrosternal burning (p<0.001), nausea (p<0.001),belching(p<0.001) and bowel habits (p<0.05),which are considered as the classical symptoms of dyspepsia. Bloating, though not a common symptom also improved (p<0.001) over time. Conclusion: The trial drug is an effective remedy for uninvestigated dyspepsia. Randomised controlled trials are further needed to confirm the pharmaco-dynamics of the trial drug for anti-ulcer, acid suppression, H-2 receptor antagonistic, anti-cholinergic properties. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 50 条
  • [21] Integrated MRSA-Management (IMM) with prolonged decolonization treatment after hospital discharge is effective: a single centre, non-randomised open-label trial
    Jahn, Bernhard
    Wassenaar, Trudy M.
    Stroh, Annemarie
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2016, 5
  • [22] The effect of tadalafil on psychosocial outcomes in Swedish men with erectile distress: a multicentre, non-randomised, open-label clinical study
    Fugl-Meyer, K. S.
    Stothard, D.
    Belger, M.
    Toll, A.
    Berglund, O.
    Eliasson, T.
    Fugl-Meyer, A. R.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (11) : 1386 - 1393
  • [23] Outcome comparison of integrated psycho-oncological care versus unstructured care-Results of a non-randomised open-label two-arm trial
    Taylor, Katherine
    Singer, Susanne
    May, Melanie
    Durdu, Guelsemin
    Petermann-Meyer, Andrea
    EUROPEAN JOURNAL OF CANCER CARE, 2019, 28 (05)
  • [24] An open-label randomised clinical trial of atorvastatin in combination with IFN Beta 1a in active multiple sclerosis patients: preliminary results
    Orefice, G.
    Quarantelli, M.
    Lanzillo, R.
    Brunetti, A.
    Salvatore, P.
    Prinster, A.
    Vacca, G.
    Mollica, C.
    Bonavita, V.
    Morra, V. Brescia
    Prinster, A.
    JOURNAL OF NEUROLOGY, 2008, 255 : 179 - 179
  • [25] Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study
    Ferrua, Francesca
    Cicalese, Maria Pia
    Galimberti, Stefania
    Giannelli, Stefania
    Dionisio, Francesca
    Barzaghi, Federica
    Migliavacca, Maddalena
    Bernardo, Maria Ester
    Calbi, Valeria
    Assanelli, Andrea Angelo
    Facchini, Marcella
    Fossati, Claudia
    Albertazzi, Elena
    Scaramuzza, Samantha
    Brigida, Immacolata
    Scala, Serena
    Basso-Ricci, Luca
    Pajno, Roberta
    Casiraghi, Miriam
    Canarutto, Daniele
    Salerio, Federica Andrea
    Albert, Michael H.
    Bartoli, Antonella
    Wolf, Hermann M.
    Fiori, Rossana
    Silvani, Paolo
    Gattillo, Salvatore
    Villa, Anna
    Biasco, Luca
    Dott, Christopher
    Culme-Seymour, Emily J.
    van Rossem, Koenraad
    Atkinson, Gillian
    Valsecchi, Maria Grazia
    Roncarolo, Maria Grazia
    Ciceri, Fabio
    Naldini, Luigi
    Aiuti, Alessandro
    LANCET HAEMATOLOGY, 2019, 6 (05): : E239 - E253
  • [26] Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings
    White, Bethany
    Little, Sophia
    Haber, Paul S.
    Roberts, Jillian
    Nolan, Erin
    Lintzeris, Nicholas
    Dunlop, Adrian J.
    DRUG AND ALCOHOL REVIEW, 2025, 44 (02) : 640 - 648
  • [27] Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
    Campforts, Bea
    Drukker, Marjan
    van Amelsvoort, Therese
    Bak, Maarten
    BMC PSYCHIATRY, 2024, 24 (01)
  • [28] Evaluation of the efficacy and safety of MRI-guided focused ultrasound (MRgFUS) for focal hand dystonia: study protocol for an open-label non-randomised clinical trial
    Maamary, Joel
    Peters, James
    Kyle, Kain
    Ruge, Diane
    Jonker, Benjamin
    Barnett, Yael
    Tisch, Stephen
    BMJ NEUROLOGY OPEN, 2023, 5 (02)
  • [29] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
    Gautret, Philippe
    Lagier, Jean-Christophe
    Parola, Philippe
    Van Thuan Hoang
    Meddeb, Line
    Mailhe, Morgane
    Doudier, Barbara
    Courjon, Johan
    Giordanengo, Valerie
    Vieira, Vera Esteves
    Dupont, Herve Tissot
    Honore, Stephane
    Colson, Philippe
    Chabriere, Eric
    La Scola, Bernard
    Rolain, Jean-Marc
    Brouqui, Philippe
    Raoult, Didier
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
  • [30] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
    Gautret, Philippe
    Lagier, Jean-Christophe
    Honore, Stephane
    Van Thuan Hoang
    Colson, Philippe
    Raoult, Didier
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)